Connect with us

Technology

Axcelis Announces Financial Results for Fourth Quarter and Full Year 2024

Published

on

Q4 Highlights:

Revenue of $252.4 millionOperating Margin of 21.6%Diluted earnings per share of $1.54

BEVERLY, Mass., Feb. 10, 2025 /PRNewswire/ — Axcelis Technologies, Inc. (Nasdaq: ACLS) today announced financial results for the fourth quarter and full year ended December 31, 2024.

For the full year 2024, the Company reported revenue of $1.02 billion, compared with $1.13 billion for the full year 2023. Systems revenue for the year was $782.6 million, compared to $883.6 million in 2023. Operating profit was $210.8 million in 2024, compared to $265.8 million in 2023. Net income for the year was $201 million with diluted earnings per share of $6.15, compared to net income of $246.3 million and diluted earnings per share of $7.43 in 2023. Gross margin for the year was 44.7%, compared to 43.5% in 2023.

The Company reported fourth quarter revenue of $252.4 million, compared to $256.6 million for the third quarter of 2024. Gross margin for the quarter was 46.0%, compared to 42.9% in the third quarter. Operating profit for the quarter was $54.5 million, compared to $46.9 million for the third quarter. Net income for the quarter was $50 million, or $1.54 per diluted share, compared to $48.6 million, or $1.49 per diluted share in the third quarter.

President and CEO Russell Low commented, “Axcelis exited the year on a strong note, with fourth quarter revenue and profitability exceeding our expectations. As we look ahead to 2025, we anticipate a near term cyclical digestion period, as customers absorb the robust investments they’ve made into mature node capacity over the past few years – particularly in China. We are focused on capturing the long-term growth opportunities that lie ahead by investing in product innovation, managing our costs, and working closely with customers on their technology roadmaps – all of which will put us in an even stronger position for the next upturn.” 

Executive Vice President and Chief Financial Officer Jamie Coogan said, “We are pleased with our financial execution in 2024. Despite a decline in revenue, we were able to deliver higher gross margins, generate solid free cash flow, return capital to shareholders via buyback, and exit the year with a stronger balance sheet that allows us to invest during this cyclical digestion period and drive long term value creation.”

Business Outlook
For the first quarter ending March 31, 2025, Axcelis expects revenues of approximately $185 million, and earnings per diluted share of approximately $0.38.

Fourth Quarter and Full Year 2024 Conference Call
The Company will host a call to discuss the results for the fourth quarter and full year 2024 on Tuesday, February 11, 2025, at 8:30 a.m. ET. The call will be available via webcast that can be accessed through the Investors page of Axcelis’ website at www.axcelis.com, or by registering as a participant here:

https://register.vevent.com/register/BIb4b94bbc1cf744869eeb20b9a9be88a7
Webcast replays will be available for 30 days following the call.

Safe Harbor Statement
This press release and the conference call contain forward-looking statements under the Private Securities Litigation Reform Act safe harbor provisions. These statements, which include our expectations for spending in our industry and guidance for future financial performance, are based on management’s current expectations and should be viewed with caution. They are subject to various risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, many of which are outside the control of the Company, including that customer decisions to place orders or our product shipments may not occur when we expect, that orders may not be converted to revenue in any particular quarter, or at all, whether demand will continue for the semiconductor equipment we produce or, if not, whether we can successfully meet changing market requirements, and whether we will be able to maintain continuity of business relationships with and purchases by major customers. Increased competitive pressure on sales and pricing, increases in material and other production costs that cannot be recouped in product pricing and instability caused by changing global economic, political or financial conditions could also cause actual results to differ materially from those in our forward-looking statements. These risks and other risk factors relating to Axcelis are described more fully in the most recent Form 10-K filed by Axcelis and in other documents filed from time to time with the Securities and Exchange Commission.

About Axcelis:
Axcelis (Nasdaq: ACLS), headquartered in Beverly, Mass., has been providing innovative, high-productivity solutions for the semiconductor industry for over 45 years. Axcelis is dedicated to developing enabling process applications through the design, manufacture and complete life cycle support of ion implantation systems, one of the most critical and enabling steps in the IC manufacturing process. Learn more about Axcelis at www.axcelis.com.

CONTACTS:

Investor Relations Contact:
David Ryzhik
Senior Vice President, Investor Relations and Corporate Strategy
Telephone: (978) 787-2352
Email: David.Ryzhik@axcelis.com

Press/Media Relations Contact: 
Maureen Hart
Senior Director, Corporate & Marketing Communications
Telephone: (978) 787-4266
Email: Maureen.Hart@axcelis.com

 

Axcelis Technologies, Inc.

Consolidated Statements of Operations

(In thousands, except per share amounts)

(Unaudited)

Three months ended 

Twelve months ended

December 31,

December 31,

2024

2023

2024

2023

Revenue:

Product

$

241,254

$

300,603

$

976,881

$

1,095,650

Services

11,163

9,685

40,984

34,954

Total revenue

252,417

310,288

1,017,865

1,130,604

Cost of revenue:

Product

125,402

163,801

524,451

608,112

Services

10,792

8,591

38,760

31,191

Total cost of revenue

136,194

172,392

563,211

639,303

Gross profit

116,223

137,896

454,654

491,301

Operating expenses:

Research and development

27,654

24,911

105,497

96, 907

Sales and marketing

16,563

16,659

68,046

62,805

General and administrative

17,475

17,275

70,317

65,794

Total operating expenses

61,692

58,845

243,860

225,506

Income from operations

54,531

79,051

210,794

265,795

Other income (expense):

Interest income

6,277

5,375

24,403

18,199

Interest expense

(1,444)

(1,320)

(5,462)

(5,347)

Other, net

(719)

4,300

539

(48)

Total other income

4,114

8,355

19,480

12,804

Income before income taxes

58,645

87,406

230,274

278,599

Income tax provision

8,689

16,350

29,282

32,336

Net income

$

49,956

$

71,056

$

200,992

$

246,263

Net income per share:

Basic

$

1.54

$

2.17

$

6.17

$

7.52

Diluted

$

1.54

$

2.15

$

6.15

$

7.43

Shares used in computing net income per share:

Basic weighted average shares of common stock

32,424

32,708

32,552

32,758

Diluted weighted average shares of common stock

32,514

33,031

32,704

33,165

 

Axcelis Technologies, Inc.

Consolidated Balance Sheets

(In thousands, except per share amounts)

(Unaudited)

December 31,

December 31,

2024

2023

ASSETS

Current assets:

Cash and cash equivalents

$

123,512

$

167,297

Short-term investments

447,831

338,851

Accounts receivable, net

203,149

217,964

Inventories, net

282,225

306,482

Prepaid income taxes

6,420

—

Prepaid expenses and other current assets

60,471

49,397

Total current assets

1,123,608

1,079,991

Property, plant and equipment, net

53,784

53,971

Operating lease assets

29,621

30,716

Finance lease assets, net

15,346

16,632

Long-term restricted cash

7,552

6,654

Deferred income taxes

68,277

53,428

Other assets

50,593

40,575

Total assets

$

1,348,781

$

1,281,967

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:

Accounts payable

$

46,928

$

54,400

Accrued compensation

25,536

31,445

Warranty

13,022

14,098

Income taxes

—

6,164

Deferred revenue

94,673

164,677

Current portion of finance lease obligation

1,345

1,511

Other current liabilities

26,018

12,834

Total current liabilities

207,522

285,129

Long-term finance lease obligation

42,329

43,674

Long-term deferred revenue

43,501

46,208

Other long-term liabilities

42,639

42,074

Total liabilities

335,991

417,085

Stockholders’ equity:

Common stock, $0.001 par value, 75,000 shares authorized; 32,365 shares issued and outstanding at December 31, 2024; 32,685 shares issued and outstanding at December 31, 2023

32

33

Additional paid-in capital

548,654

547,189

Retained earnings

470,318

319,506

Accumulated other comprehensive loss

(6,214)

(1,846)

Total stockholders’ equity

1,012,790

864,882

Total liabilities and stockholders’ equity

$

1,348,781

$

1,281,967

 

Axcelis Technologies, Inc.

Condensed Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

Three months ended

Twelve months ended

December 31,

December 31,

2024

2023

2024

2023

Cash flows from operating activities

Net income

$

49,956

$

71,056

$

200,992

$

246,263

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization

4,267

3,581

15,809

13,069

Stock-based compensation expense

5,380

5,239

20,951

18,269

Other

(442)

(14,565)

(11,532)

(23,503)

Change in operating assets and liabilities, net

(46,381)

264

(85,402)

(97,229)

Net cash provided by operating activities

12,780

65,575

140,818

156,869

Cash flows from investing activities

Expenditures for property, plant and equipment and capitalized software

(4,658)

(10,153)

(12,181)

(20,656)

Other changes in investing activities, net

13,779

(16,526)

(96,545)

(80,202)

Net cash provided by (used in) investing activities

9,121

(26,679)

(108,726)

(100,858)

Cash flows from financing activities

Repurchase of common stock

(15,131)

(15,001)

(60,489)

(52,499)

Other changes from financing activities, net

588

(22)

(10,703)

(15,769)

Net cash used in financing activities

(14,543)

(15,023)

(71,192)

(68,268)

Effect of exchange rate changes on cash and cash equivalents

(3,013)

1,128

(3,787)

(139)

Net increase (decrease) in cash, cash equivalents and restricted cash

4,345

25,001

(42,887)

(12,396)

Cash, cash equivalents and restricted cash at end of period

$

131,064

$

173,951

$

131,064

$

173,951

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/axcelis-announces-financial-results-for-fourth-quarter-and-full-year-2024-302371721.html

SOURCE Axcelis Technologies, Inc.

Continue Reading

Technology

Best AI Tools for Marketing Content (2026): CapCut Recognized for Faster AI-Powered Video and Image Creation by Better Business Advice

Published

on

By

NEW YORK, Oct. 24, 2026 /PRNewswire/ — Better Business Advice has recognized CapCut in its 2026 coverage of the best AI tools for marketing content, highlighting its collection of AI-powered features for creating and editing videos, images, audio, and other campaign assets. The recognition reflects growing interest in tools that help transform creative concepts into usable marketing materials while reducing the manual work involved in production.

Best AI Marketing Tools

Seedance 2.0 – an AI video generation model that creates videos from text prompts or imagesSeedream – an AI image generation model that creates high-quality visuals from text prompts

AI-powered content creation is changing how businesses develop digital marketing campaigns. From promotional videos and product imagery to social media graphics and branded audio, organizations face growing demand for creative assets across multiple digital channels. Tools that simplify production and support faster experimentation are becoming an increasingly important part of modern marketing workflows.

CapCut offers a range of AI-assisted capabilities covering several stages of content creation. These include text-based video generation, AI image generation, background removal, image expansion, music generation, and photo animation. Together, the tools provide options for producing marketing assets for social media, digital advertising, product promotions, and other online campaigns.

AI Video Generation Supports Promotional Campaigns

Video is an important format for communicating product information, presenting services, and building audience engagement. However, producing video content regularly can require significant planning, editing, and creative resources.

CapCut’s Seedance 2.0 AI video generator supports prompt-based video creation. Users can describe a creative concept and generate video content that serves as a starting point for further development.

The capability can support promotional videos, product showcases, educational content, and social media campaigns. It also gives creators a way to explore different visual approaches during the planning stage before refining the selected direction.

For businesses producing content across multiple channels, AI-assisted video generation can help reduce the effort required to develop initial concepts. Generated material can then be reviewed and edited to align with campaign objectives, brand guidelines, and platform requirements.

Image Generation Helps Develop Marketing Concepts

Visual assets influence how products, services, and campaigns are presented to audiences. Developing suitable imagery often involves several rounds of brainstorming and creative testing before a final direction is selected.

CapCut’s Seedream AI image generator enables users to create images from text prompts. The tool can support concept drafts, campaign planning, and experimentation with different visual styles.

For example, a seasonal marketing campaign may require several approaches to backgrounds, compositions, and visual themes. AI-generated drafts can help illustrate those options before resources are committed to final production.

CapCut’s GPT Image 2 provides another option for generating images from natural language instructions. The feature can support the development of promotional graphics, campaign imagery, and other visual assets.

These tools help shorten the early stages of creative development by making it easier to turn written ideas into visual references. Human review remains important to ensure the resulting assets accurately represent the product and meet the campaign’s requirements.

Image Editing Simplifies Asset Preparation

AI image generation is only one part of preparing content for publication. Existing photographs and graphics often need adjustments before they can be used across marketing channels.

CapCut’s AI background removal tool helps separate subjects from their original backgrounds. This can be useful when preparing product images, promotional graphics, and other assets that require a different visual setting.

The AI Image Extender addresses the challenge of adapting images to different layouts. By generating content beyond an image’s original boundaries, the tool can help users adjust compositions for different formats without relying entirely on cropping or stretching.

These capabilities can support the preparation of visuals for social media posts, website banners, digital advertisements, and product promotions. They also provide options for repurposing existing creative assets instead of producing entirely new images for every placement.

AI Audio and Photo Animation Expand Creative Options

Marketing content often combines visuals, movement, and sound to communicate a message. Producing these elements separately can add complexity to the creative process.

CapCut’s SeedMusic AI audio generator supports AI-assisted music creation based on creative prompts. Generated music can be used as a starting point for videos, promotional campaigns, and other multimedia projects, subject to appropriate review and usage requirements.

The platform’s Photo-to-3D tool offers another way to adapt still images into more dynamic visual content. This capability can help transform existing photography into animated presentations for product showcases, social media, and digital promotions.

By supporting audio creation and image animation alongside video and image tools, CapCut provides additional options for developing varied marketing materials.

A Connected Workflow for Marketing Content

CapCut’s collection of AI-powered features supports several stages of campaign production within one creative environment. A project could begin with concept images generated through Seedream, followed by visual development with GPT Image 2. Background removal and image expansion can then help prepare assets for different placements.

Selected visuals can be incorporated into video projects using Seedance 2.0, while SeedMusic offers an option for developing accompanying audio. Photo-to-3D can provide another format for repurposing existing images.

Not every campaign requires all these capabilities. Their practical value depends on the content format, production requirements, and intended audience. Reviewing generated assets for accuracy, visual consistency, and suitability remains essential before publication.

Better Business Advice’s recognition of CapCut reflects the growing role of AI-assisted production in digital marketing. As businesses continue to develop content for multiple channels, tools that support video creation, image generation, editing, and multimedia production can help simplify creative workflows while leaving room for human direction and quality control.

The full article can be read at the Better Business Advice website.

About CapCut

CapCut is an AI-powered photo and video editing platform designed to make high-quality video creation accessible across devices. The platform supports creators, businesses, and everyday users with tools for video editing, AI video generation, captions, templates, audio, and visual editing. CapCut is available across mobile, web, desktop, and iPad experiences, helping users create, edit, and prepare video content for social media, marketing, education, and personal projects.

About Better Business Advice: Better Business Advice covers the news and strategies driving modern business success. The information provided by Better Business Advice does not, and is not intended to, constitute legal advice; instead, all information, content, and materials are for general informational purposes only. As an affiliate, Better Business Advice may earn commissions from services mentioned in the links provided.

View original content:https://www.prnewswire.com/news-releases/best-ai-tools-for-marketing-content-2026-capcut-recognized-for-faster-ai-powered-video-and-image-creation-by-better-business-advice-302918030.html

SOURCE BetterBusinessAdvice.com

Continue Reading

Technology

Bio-Thera Announces Promising Clinical Data for BAT8008 in Combination with BAT1308 in First-Line Non-Small Cell Lung Cancer at ESMO 2026

Published

on

By

GUANGZHOU, China, Oct. 24, 2026 /PRNewswire/ — Bio-Thera Solutions, Ltd. (688177.SH), a commercial-stage biopharmaceutical company developing innovative therapies and biosimilars, today announced the presentation of clinical data for BAT8008, a TROP2-targeted antibody-drug conjugate (ADC), in combination with BAT1308, an anti-PD-1 monoclonal antibody, at the 2026 European Society for Medical Oncology (ESMO) Congress. Professor Shaodong Hong of Sun Yat-sen University Cancer Center delivered a rapid oral presentation highlighting results from the combination regimen in patients with non-small cell lung cancer (NSCLC). Further details are available on Bio-Thera’s official website.

In the first-line, mutation-negative NSCLC population (N=104), treatment with BAT8008 in combination with BAT1308 achieved an objective response rate (ORR) of 61.2% and a median progression-free survival (PFS) of 12.42 months. In the non-squamous NSCLC subgroup, the ORR was 65.2%, while median PFS had not yet been reached at the time of analysis. The combination demonstrated a manageable safety profile consistent with the known safety characteristics of the individual agents, with no new safety signals identified.

“We are very encouraged by these Phase 2 results evaluating BAT8008 in combination with BAT1308 as a first-line treatment for advanced non-small cell lung cancer”, said Shengfeng Li, CEO of Bio-Thera Solutions.  “The findings support the potential of this combination approach in First Line NSCLC and reinforce our commitment to advancing innovative oncology therapies for patients with significant unmet medical needs.”

Lung cancer remains a major global health challenge, and NSCLC accounts for the majority of lung cancer cases. Patients with advanced NSCLC who lack actionable genomic alterations continue to face significant treatment challenges, despite advances in immunotherapy and chemoimmunotherapy. New treatment strategies that can improve clinical outcomes while maintaining a manageable safety profile remain an important area of oncology research.

TROP2-targeted ADCs combine tumor-directed delivery of cytotoxic payloads with the potential to modulate the tumor microenvironment. When combined with PD-1 blockade, this approach may offer complementary mechanisms of action, providing a rationale for clinical investigation in NSCLC. The clinical findings presented at ESMO 2026 support further evaluation of BAT8008 in combination with BAT1308 as a potential treatment option for patients with NSCLC.

About Bio-Thera Solutions:

Bio-Thera Solutions, Ltd., a leading innovative, global biopharmaceutical company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular, eye diseases, and other severe unmet medical needs, as well as biosimilars for existing, branded biologics to treat a range of cancer and autoimmune diseases. As a leader in next generation antibody discovery and engineering, the company has advanced multiple candidates into late-stage development, including six approved products: QLETLI® (adalimumab) and BETAGRIN® (bevifibatide citrate) Injection in China, STARJEMZA® (ustekinumab) in the US and USYMRO® (ustekinumab) in the EU, TOFIDENCE®/BAT1806 (tocilizumab) and AVZIVI® (bevacizumab-tnjn) in the US and in the EU, a/k/a POBEVCY® in China, and GOTENFIA® (golimumab) in the EU and IMMGOLIS™ (golimumab-sldi) in the US. In addition, the company has more than 20 promising candidates in clinical trials, focusing on immuno-oncology in the post-PD-1 era and targeted therapies such as antibody-drug conjugates (ADCs). For more information, please visit www.bio-thera.com/en/ or follow us on X (@bio_thera_sol) and WeChat (Bio-Thera).

Bio-Thera Cautionary Note Regarding Forward-Looking Statements

This news release contains certain forward-looking statements relating to BAT8008, BAT1308 or the product pipelines in general of Bio-Thera Solutions. Readers are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. The forward-looking statements include, among others, those containing “could,” “may,” “should,” “will,” “would,” “anticipate,” “believe,” “plan,” “promising,” “potentially,” or similar expressions. They reflect the company’s current views with respect to future events that are based on what the company believes are reasonable assumptions in view of information currently available to Bio-Thera Solutions, and are not a guarantee of future performance or developments. Actual results and events may differ materially from information contained in the forward-looking statements as a result of a number of factors, including, but not limited to, risks and uncertainties inherent in pharmaceutical research and development, such as the uncertainties of pre-clinical and clinical studies. Other risks and uncertainties include challenges in obtaining regulatory approvals, manufacturing, marketing, competition, intellectual property, product efficacy or safety, changes in global healthcare situation, changes in the company’s financial conditions, and changes to applicable laws and regulations, etc. Forward-looking statements contained herein are made only as of the date of their initial publication. Unless required by laws or regulations, Bio-Thera Solutions undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, changes in the company’s views or otherwise.

Bio-Thera Contact:
Bert E. Thomas IV
Phone: +1.410.627.1734
Email: bethomas@bio-thera.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-thera-announces-promising-clinical-data-for-bat8008-in-combination-with-bat1308-in-first-line-non-small-cell-lung-cancer-at-esmo-2026-302918492.html

SOURCE Bio-Thera Solutions, Ltd

Continue Reading

Technology

ASTRI Showcases Pioneering Technologies at InnoCarnival 2026

Published

on

By

Driving Technology Adoption, Shaping a Vision for the Future

HONG KONG, Oct. 24, 2026 /PRNewswire/ — The Hong Kong Applied Science and Technology Research Institute (ASTRI) is proud to present a range of cutting-edge technologies and practical solutions at this year’s InnoCarnival, spanning communications technology, smart cities, IoT sensing, and renewable energy and energy storage. ASTRI’s innovations address urban development needs and everyday applications, driving diversity in the innovation and technology (I&T) sector.

Organised by the Innovation and Technology Commission of the Hong Kong SAR Government, the InnoCarnival 2026 runs from today through 1 November at Hong Kong Science Park (HKSP) with the theme of “Lead with I&T, Dream to Fly High “, offering the public an opportunity to experience the transformative power and I&T vibrancy.

Ir Dr Ted Suen, Chief Executive Officer of ASTRI, stated: “Innovation is not just about breakthroughs in the lab – it’s about putting technology into practice, empowering industries, and benefiting society as a whole. At ASTRI, we align closely with the government’s priorities in advancing AI development and accelerating new industrialisation. Through our participation in the InnoCarnival, we showcase various state-of-the-art technologies, some of which have been co-developed with industry partners and are already in commercial rollout. These innovations demonstrate the tangible benefits of technology in daily life and inspire the public to explore their curiosity about science and innovation.”

He highlighted the InnoCarnival as a key platform to bridge the I&T community with the public. “This annual landmark event motivates young people to explore their potential and encourages them to pursue careers in Hong Kong’s growing I&T sector,” he added.

ASTRI’s booth (A08), located at the HKSP’s Atrium Link, features interactive games powered by its groundbreaking technologies “5G-SAT Link” and “Omniguard-All-Weather Multispectral Surveillance System” technologies. Visitors can also explore other advanced solutions on display, including the dual-purpose “SafeStop Dual-purpose Impact Dissipation Bollard”, the “Hybrid-Powered Asset Tracker”, and the award-winning “NIR Secure Anti-Counterfeit Solutions”, which received gold award at the prestigious Edison Awards.

1. 5G-SAT Link
ASTRI’s “5G-SAT Link” technology delivers seamless, comprehensive communications coverage—even in remote areas, emergency scenarios where infrastructure is compromised, or at sea and in the air.

2. Omniguard: All-Weather Multispectral Surveillance System
The “Omniguard” is equipped with exceptional fog penetration capabilities, superior contrast, and crystal-clear signal quality. Leveraging its advanced shortwave and longwave infrared sensors, the system can even detect non-metallic vessels that are difficult for radar systems to identify in harsh coastal environments.

3. SafeStop Dual-purpose Impact Dissipation Bollard
Developed by ASTRI, the “SafeStop Bollard” features a unique material design inspired by the retractable claw structure of cats. Its 3D tension-expansion composition allows it to effectively dissipate kinetic energy from moving vehicles, providing dual protection by blocking vehicles while minimising potential harm to occupants. Certified to meet international crash-test standards, the bollard’s shallow foundation design makes it ideal for fast and efficient installation in high-traffic urban locations.

4. Hybrid-Powered Asset Tracker
The “Hybrid-Powered Asset Tracker” enables efficient, real-time management of airport equipment such as baggage carts over extended periods. Supported by the Airport Authority Hong Kong, the tracker is compatible with airport wireless networks and utilises automatic Bluetooth-GPS switching for seamless indoor and outdoor location updates. With a long-lasting battery combined with an efficient, low-light solar panel, the tracker extends its lifespan from under two years to five years.

5. NIR Secure Anti-Counterfeit Solutions
The “NIR Secure Anti-Counterfeit Solutions” offer an innovative authentication system by embedding covert near-infrared (NIR) absorbing materials into product packaging. Users can verify product authenticity instantly using a smartphone, paired with an NIR reader and mobile app. Highly scalable and robust, this solution combats counterfeit goods while preserving the original product design and production workflow. Co-developed with Zhuhai Print-Rite New Materials Corporation Ltd., this technology sets a new benchmark in secure authentication.

Photos Download: https://bit.ly/4iguifh

About ASTRI

Founded in 2000 by the HKSAR Government, Hong Kong Applied Science and Technology Research Institute (ASTRI) is the city’s largest government-funded R&D centre. Committed to transforming high-impact research into practical innovations, ASTRI drives market-driven, interdisciplinary advancements across sectors, including Smart City, FinTech, Digital Health and Life Sciences, New Industrialisation and Intelligent Manufacturing, Application-Specific Integrated Circuits (ASIC) and Advanced Electronics, New Energy and Energy Storage, and Green and ESG Technologies. Following its merger with the Nano and Advanced Materials Institute, ASTRI has further strengthened its capabilities, with over 1,500 patents and 2,200 successful cases of technology transfer. Recognised with numerous international awards, ASTRI continues to nurture top I&T talent and foster collaborations among the I&T ecosystem, contributing to Hong Kong’s high-value economic development. For more information, please visit: https://www.astri.org 

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/astri-showcases-pioneering-technologies-at-innocarnival-2026-302918617.html

SOURCE Hong Kong Applied Science and Technology Research Institute (ASTRI)

Continue Reading

Trending